ESTRO 2024 - Abstract Book

S4672

Physics - Optimisation, algorithms and applications for ion beam treatment planning

ESTR0 2024

2. Siva, S., et al., 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Lancet Oncol, 2022. 23(12): p. 1508-1516. 3. Siva, S., et al., Stereotactic Body Radiotherapy for Large Primary Renal Cell Carcinoma: A Report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). International Journal of Radiation Oncology*Biology*Physics, 2019. 105(1): p. E257-E258.

4. Turajlic, S., et al., Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal.Cell, 2018. 173(3): p. 581-594 e12.

5. Berghen, C., et al., The role of radiation therapy and particle therapy in renal cell carcinoma: current evidence and future perspectives. Journal of Cancer Metastasis and Treatment, 2021.

6. Ishikawa, H., et al., A Japanese registry study and systematic review of particle therapy for renal cell carcinoma. J Radiat Res, 2023. 64(Supplement_1): p. i41-i48.

7. Malouff, T.D., et al., Carbon Ion Therapy: A Modern Review of an Emerging Technology. Front Oncol, 2020. 10: p. 82.

8. De Meerleer, G., et al., Radiotherapy for renal-cell carcinoma. Lancet Oncol, 2014. 15(4): p. e170-7

9. Shinoto, M., et al., Dosimetric analysis of upper gastrointestinal ulcer after carbon-ion radiotherapy for pancreatic cancer. Radiother Oncol, 2016. 120(1): p. 140-4.

2230

Digital Poster

Beyond a constant proton RBE: Survey on clinical and research activities in Europe and United States

Jakob Ödén, Kjell Eriksson, Suryakant Kaushik, Erik Traneus

RaySearch Laboratories AB, Research, Stockholm, Sweden

Purpose/Objective:

The proton relative biological effectiveness (RBE) depends on several factors such as proton energy, linear energy transfer (LET), tissue characteristics, dose parameters, and the specific biological endpoint under consideration. In clinical practice, a constant RBE of 1.1 is routinely assumed, potentially leading to suboptimal treatment outcomes in terms of both tumour control and normal tissue toxicity. This study aims to provide a comprehensive overview of the current clinical practices, ongoing research initiatives, and the potential for incorporating variable proton RBE and associated parameters within the framework of a survey among proton therapy institutions in Europe and the United States.